Literature DB >> 15486999

Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease.

Daniela Berg1, Berthold Merz, Karlheinz Reiners, Markus Naumann, Georg Becker.   

Abstract

Using transcranial sonography, an area of hyperechogenicity at the substantia nigra (SN) may be detected as a typical marker in patients with Parkinson's disease (PD) as well as in approximately 9% of healthy subjects vulnerable to nigrostriatal impairment. In this longitudinal study, we provide evidence that the area of SN hyperechogenicity does not change in the course of PD. In conjunction with earlier findings in children and adolescents, this evidence indicates that, from late adolescence onward, this ultrasound finding is a trait marker for nigrostriatal vulnerability. 2004 Movement Disorder Society.

Entities:  

Mesh:

Year:  2005        PMID: 15486999     DOI: 10.1002/mds.20311

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  52 in total

Review 1.  Neuroimaging in Parkinson's disease.

Authors:  A Jon Stoessl
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

Review 2.  Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: no.

Authors:  Uwe Walter
Journal:  J Neural Transm (Vienna)       Date:  2010-12-29       Impact factor: 3.575

Review 3.  Advances in Biomarker Research in Parkinson's Disease.

Authors:  Shyamal H Mehta; Charles H Adler
Journal:  Curr Neurol Neurosci Rep       Date:  2016-01       Impact factor: 5.081

Review 4.  Early diagnosis of Parkinson's disease.

Authors:  Jörg Spiegel; Alexander Storch; Wolfgang H Jost
Journal:  J Neurol       Date:  2006-08       Impact factor: 4.849

5.  In vivo detection of iron and neuromelanin by transcranial sonography--a new approach for early detection of substantia nigra damage.

Authors:  D Berg
Journal:  J Neural Transm (Vienna)       Date:  2006-05-18       Impact factor: 3.575

6.  Long-Term Follow-up Investigation of Isolated Rapid Eye Movement Sleep Without Atonia Without Rapid Eye Movement Sleep Behavior Disorder: A Pilot Study.

Authors:  Ambra Stefani; David Gabelia; Birgit Högl; Thomas Mitterling; Philipp Mahlknecht; Heike Stockner; Werner Poewe; Birgit Frauscher
Journal:  J Clin Sleep Med       Date:  2015-11-15       Impact factor: 4.062

7.  Transcranial sonography image characteristics in different Parkinson's disease subtypes.

Authors:  Ai Yan Sheng; Ying Chun Zhang; Yu Jing Sheng; Cai Shan Wang; Ying Zhang; Hua Hu; Wei Feng Luo; CHun-Feng LIu
Journal:  Neurol Sci       Date:  2017-07-19       Impact factor: 3.307

8.  Transcranial sonography in spinocerebellar ataxia type 2.

Authors:  Milija Mijajlović; Natasa Dragasević; Elka Stefanova; Igor Petrović; Marina Svetel; Vladimir S Kostić
Journal:  J Neurol       Date:  2008-05-07       Impact factor: 4.849

9.  Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.

Authors:  Shunit Gal; Hailin Zheng; Mati Fridkin; Moussa B H Youdim
Journal:  Neurotox Res       Date:  2009-07-16       Impact factor: 3.911

10.  T1rho and T2rho MRI in the evaluation of Parkinson's disease.

Authors:  I Nestrasil; S Michaeli; T Liimatainen; C E Rydeen; C M Kotz; J P Nixon; T Hanson; Paul J Tuite
Journal:  J Neurol       Date:  2010-01-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.